Tag: Pradaxa
EMA issues positive opinion for updated dabigatran summary of characteristics
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to...
Final Phase III results support safety of idarucizumab as reversal agent...
Final results from RE-VERSE AD study show that idarucizumab, marketed in the US as Praxbind (Boehringer Ingelheim), was able to immediately reverse the anticoagulant...
Patient enrolment complete in study assessing use of dabigatran atrial fibrillation...
Patient enrolment into the international Phase IIIb RE-DUAL PCI study is complete. The study is evaluating the safety and efficacy of dabigatran (Pradaxa, Boehringer...